Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Zimmer Biomet (ZBH) reported revenue of $2 billion, up 9.7% over the same period last year. EPS came in at $1.90, compared to $1.74 in the year-ago quarter.The reported revenue represents a surprise of -0.42% over the Zacks Consensus Estimate of $2.01 billion. With the consensus EPS estimate being $1.88, the EPS surprise was +1.06%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Knees- United States: $440.1 million versus the four-analyst average estimate of $443.24 million. The reported number represents a year-over-year change of +3.5%.Net Sales- Hips- United States: $264.7 million versus $265.2 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.Net Sales- Hips- International: $241.5 million versus $244.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.Net Sales- Knees- International: $352.3 million versus $347.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.Net Sales- International: $837.3 million compared to the $850.8 million average estimate based on three analysts. The reported number represents a change of +8.5% year over year.Net Sales- United States: $1.16 billion versus $1.15 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.Net Sales- Knees: $792.4 million versus the seven-analyst average estimate of $788.1 million. The reported number represents a year-over-year change of +6.4%.Net Sales- Technology & Data, Bone Cement and Surgical: $161.3 million compared to the $160.61 million average estimate based on seven analysts.Net Sales- S.E.T: $541.5 million versus $552.12 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +19.2% change.Net Sales- Hips: $506.2 million compared to the $508.21 million average estimate based on seven analysts. The reported number represents a change of +5.1% year over year.View all Key Company Metrics for Zimmer here>>>Shares of Zimmer have returned +4.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks